The Earlier You Know, the More You Can Do: Why an Alzheimer’s Diagnosis Matters

Alzheimer’s disease starts long before anyone notices it. The changes in the brain that eventually show up as memory lapses, confusion or personality shifts can start a decade or more before a diagnosis is ever made. That quiet gap between what happens in the brain and what a family actually sees is at the heart of this year’s World Alzheimer’s Day message: the earlier you know, the more you can do.

That message carries more weight today because the treatment landscape is changing. Researchers are developing treatments for people earlier in the course of the disease, biomarkers are helping identify patients more precisely, and new treatments are also emerging for some of the difficult behavioral symptoms that families encounter as Alzheimer’s progresses.

For patients and caregivers, an earlier diagnosis can mean more time to understand the disease, consider available treatments, participate in clinical trials and make decisions together. For drug developers, it can mean reaching patients while there is still a greater opportunity to preserve function or slow decline.

The Race to Intervene Before More Function Is Lost

Anavex Life Sciences (NASDAQ: AVXL) has spent years developing an oral treatment called blarcamesine, targeting people in early stages of Alzheimer’s disease. The company’s research has focused on a small subset of early-stage patients with confirmed but not yet advanced disease pathology– the same population that early-detection programs are designed to target.

The results so far certainly speak directly to the “earlier is better” argument. New data presented in 2026 showed a consistent relationship between blarcamesine’s effect and brain volume preservation in early Alzheimer’s patients. Long-term follow-up data showed that patients on the treatment experienced significantly slower decline than would be expected without it, which the company estimates at more than a year and a half of time saved. In the most precisely defined patient group, cognitive decline after about a year of treatment was described by the company as minor, comparable to normal aging rather than disease progression. Those findings come from company analyses of a defined patient subgroup. In December 2025, the European Medicines Agency recommended against approving blarcamesine after concluding the main study did not meet its primary objective, and Anavex withdrew its European application in March 2026 before a re-examination was completed.

None of this works without patients being identified early enough to enroll. It’s a real-world example of why the diagnosis timeline isn’t just a medical detail— it’s the difference between a treatment having something to work with and not.

Alzamend Neuro (NASDAQ: ALZN) is taking a different scientific approach, with two treatments in development side by side. One is AL001, a new version of lithium for Alzheimer’s and a whole array of neuropsychiatric diseases that the company believes could prove safer and more effective than existing lithium treatments. The other is a cell-based vaccine that targets the immune system to recognize and resist the disease process behind Alzheimer’s.

Early studies of AL001 showed bioequivalent lithium exposure in the blood and numerically higher lithium concentrations across measured brain regions compared with standard lithium carbonate, and further studies in Alzheimer’s patients are planned. The vaccine program has been delayed, with a paused trial that is expected to resume, a reminder that the path from an early scientific idea to an available treatment is rarely a straight line— even in the face of promising science.

Annovis Bio (NYSE: ANVS) is testing the early-intervention approach at a much larger scale. Its pivotal Phase 3 study of buntanetap in early Alzheimer’s disease is fully enrolled with 850 patients, exceeding the original target of 760. Participants have early Alzheimer’s disease and are positive for the plasma pTau217 biomarker, providing confirmation of amyloid and tau pathology.

The study is evaluating both cognition and function, with six-month symptomatic topline data expected in the first quarter of 2027 and longer-term follow-up designed to assess potential disease-modifying effects.

Together, the programs reflect an important shift in Alzheimer’s research. It is increasingly not enough to identify that someone has cognitive decline. Drug development is moving toward determining who has the underlying disease, how early it can be identified and whether treatment at that stage can change what happens next.

A New Treatment Benchmark for Alzheimer’s Agitation

The need for treatment does not end with cognitive decline. Agitation can become one of the most difficult manifestations of Alzheimer’s dementia for patients, caregivers and families.

That part of the treatment landscape changed this year when Axsome Therapeutics (NASDAQ: AXSM) received FDA approval for Auvelity for agitation associated with dementia due to Alzheimer’s disease. The approval made Auvelity the first non-antipsychotic treatment approved for the indication.

The approval was supported by Phase 3 studies evaluating reductions in agitation symptoms and the durability of treatment response. For families managing Alzheimer’s, the significance is practical. Treating the disease also means addressing symptoms that can affect daily care, independence and quality of life.

IGC Pharma (NYSE American: IGC) is pursuing the same clinical problem from an earlier stage of development. Its investigational IGC-AD1 is being evaluated in the randomized, placebo-controlled Phase 2 CALMA trial for agitation associated with Alzheimer’s dementia.

As of its Q2 2026 update, CALMA had reached its original 146-patient randomization target and was nearing completion of additional planned enrollment, with topline results expected in the fourth quarter of 2026. The readout will provide an important test of IGC-AD1 in an indication where an approved non-antipsychotic option has now established a new treatment benchmark.

From Earlier Diagnosis to More Ways to Intervene

World Alzheimer’s Day is not just about raising money or wearing a ribbon. It is about changing the way people think about memory concerns before they become a crisis. A diagnosis, even a challenging one, opens doors: to treatment options for early-stage disease, to clinical trials that need early-stage participants to succeed, and to time for a family to plan and make decisions together.

The science is moving in the same direction as the public health message. Treatments are being developed for people who are caught early, and so the case for talking to a doctor about memory changes sooner rather than later has never been stronger. If you or someone you love is noticing changes in memory or thinking, that conversation with a doctor is worth having now — not after the symptoms become undeniable.